Hepatitis B Which ARV regimen should be recommended? Should this be continued after delivery? What is the preferred mode of delivery for women with HBV coinfection? Should CP-690550 in vitro all infants born to hepatitis B coinfected mothers receive (a) hepatitis B vaccination; (b) hepatitis B immune globulin? Should pregnant women with HBV be vaccinated against HAV? Hepatitis C Which ARV regimen should be recommended? Should this be continued after delivery? What is the preferred mode of delivery
for women with HCV coinfection? Should pregnant women Buparlisib with HCV be vaccinated against HBV and HAV? Is there a place for treating hepatitis C in pregnancy to prevent MTCT of hepatitis C? Should these women be monitored in any additional way compared to those not coinfected? Should the HCV be treated? Study design: SRs, RCTs, observational, risk, economic Population: HIV-positive women Intervention: obstetric delivery and fetal monitoring Comparator: none Outcomes: death, AIDS, non-AIDS
co-morbidities, maternal obstetric morbidity, infant mortality and morbidity, mother-to-child HIV transmission, drug resistance Mode of delivery At what level would a HIV viral load be ‘safe’ for vaginal delivery? When should a CS be performed?
What ART should be given during delivery Obstetric procedures When should VBAC be regarded as ‘safe’? Is it safe to perform ECV, induction of labour, instrumental delivery, episiotomy in HIV-positive Progesterone pregnant women? What fetal monitoring tests should be performed during delivery? Trisomy/anomaly screening tests, amniocentesis and chorionic villus sampling Which tests are most appropriate for use in HIV-positive women? What should be the ARV management of a woman requiring amniocentesis or chorionic villus sampling who is not yet on ART Ruptured membranes What is the optimum ART and obstetric management for women presenting with both term and preterm ROMs? Study design: SRs, RCTs, observational, risk, economic Population: HIV-exposed infants Intervention: ART and prophylaxis for neonates Comparator: none Outcomes: death, AIDS, non AIDS co-morbidities, infant mortality and morbidity, mother-to-child HIV transmission, drug resistance.